AstraZeneca Pharmaceuticals LP v. Aurobindo Pharma Limited Inc.
1:08-cv-00359
Overview
Parties
Movant
AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)
Represented By
4 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
McCarter & English LLP
Four Gateway Center, 100 Mulberry Street
Defendant
Aurobindo Pharma Limited Inc. NPE (University / Research)
Represented By
7 Attorneys ListedBayard, P.A.
Bayard, P.A., 222 Delaware Avenue, Suite 900
Bayard, P.A.
Bayard, P.A., 222 Delaware Avenue, Suite 900
Aurobindo Pharma USA Inc. Operating Company
Represented By
4 Attorneys ListedBayard, P.A.
Bayard, P.A., 222 Delaware Avenue, Suite 900
Bayard, P.A.
Bayard, P.A., 222 Delaware Avenue, Suite 900
Plaintiff
Shionogi Seiyaku Kabushiki Kaisha Operating Company
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
McCarter & English LLP
Four Gateway Center, 100 Mulberry Street
IPR Pharmaceuticals Inc. Operating Company
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
McCarter & English LLP
Four Gateway Center, 100 Mulberry Street
AstraZeneca UK Limited NPE (University / Research)
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
McCarter & English LLP
Four Gateway Center, 100 Mulberry Street
Counter Claimant
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° RadarMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
No Co-Pending Disputes Detected in Current Index
There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
USRE37314
Pyrimidine derivatives
|
Filed: 1998-08-27
Issued: 2001-08-07
|
Expired (Term Ended)
Expires: 2016-01-08
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
47
Dispositive
25
Granted
2
Denied
2
Pending / Review
42
Motions by Category
Key Dispositive Motions & Rulings